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Edited by Vladimir SkulachevAbstract Hypoxia inducible factor-1a (HIF-1a) is a central
component of the cellular responses to hypoxia. Hypoxic condi-
tions result in stabilization of HIF-1a and formation of the trans-
criptionally active HIF-1 complex. It was suggested that
mammalian ARD1 acetylates HIF-1a and thereby enhances
HIF-1a ubiquitination and degradation. Furthermore, ARD1
was proposed to be downregulated in hypoxia thus facilitating
the stabilization of HIF-1a. Here we demonstrate that the level
of human ARD1 (hARD1) protein is not decreased in hypoxia.
Moreover, hARD1 does not acetylate and destabilize HIF-1a.
However, we ﬁnd that hARD1 speciﬁcally binds HIF-1a,
suggesting a putative, still unclear, connection between these
proteins.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Survival of mammalian cells is dependent on the adequate
supply of oxygen and nutrients which are provided by a well
organized vascular network. Precise homeostatic control
mechanisms continuously adjust the blood ﬂow to maintain
adequate oxygen tension, pH and appropriate concentrations
of glucose and other nutrients [1]. This balance is lost in solid
tumours, where the process of tumour expansion exceeds the
development of blood vessels resulting in a hypoxic microenvi-
ronment [2,3]. Successful tumour progression depends on bio-
chemical adaptation and genetic alterations that will promote
tumour survival despite this unfavourable microenvironment
[4]. Central to the adaptation of cells to hypoxia is the activa-
tion of the transcriptional complex HIF-1 (hypoxia-inducible
complex-1) [5]. HIF-1 controls the transcriptional response
of a plethora of genes involved in angiogenesis and glucoseAbbreviations: ARD, arrest-defective (homologue of yeast Ard1p);
NAT, N-acetyltransferase; NATH, NAT human; hARD1, human
ARD1; HIF-1a, hypoxia inducible factor 1a
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poxia and promote tumour survival [6,7]. The HIF complex is
composed of an oxygen-regulated HIF-1a subunit and a
constitutively expressed HIF-1b subunit [8]. In normoxic con-
ditions the HIF-1a protein is degraded by the ubiquitin-
proteasome system in a process that involves its interaction
with VHL (Von Hippel Lindau), a tumour suppressor protein
that acts as a ubiquitin-ligase (E3) [9,10]. HIF-1a/VHL inter-
actions depend on the oxygen-mediated hydroxylation of
prolyl-residues in the oxygen degradation domain of HIF-1a
(HIF-ODD). In the presence of oxygen, HIF-1a is hydroxyl-
ated at prolyl-residues P402 and P564 by speciﬁc oxygen-
and iron-dependent hydroxylases (PHDs), thus promoting
HIF-1a ubiquination and degradation [11]. During hypoxia,
HIF-1a is not degraded and interacts with HIF-1b to form a
transcriptionally active DNA-binding complex. Although hy-
poxia is the main regulator of HIF-1a, an array of factors
including cytokines, growth factors and oncogenic mutations
have also been shown to induce HIF-1a and control HIF-1
complex formation. These factors appear to have an important
role in the non-hypoxic expression of HIF-1a in tumours and
inﬂammatory responses [12,13]. The mechanisms of HIF-1a
induction in these conditions is not clear and may involve
other post-translational modiﬁcations of the HIF-1a protein
like phosphorylation or acetylation.
One of the proposed non-hypoxic regulators of HIF-1a is
the acetyltransferase hARD1 [14]. hARD1 was shown to acet-
ylate the e-amino group of lysine residue K532 within the
ODD domain of HIF-1a, enhancing the binding of pVHL
and the subsequent proteasomal degradation of HIF-1a. Dur-
ing hypoxia, hARD1 mRNA was found to decrease and the
interaction between HIF-1a and hARD1 was diminished.
Thus, the conclusion was made that in hypoxia the hARD1
mediated negative regulation was reduced and stabilization
of HIF-1a was allowed. hARD1 has been described to be a
subunit of a protein N-a-acetyltransferase complex [15]. The
two proteins constituting the enzyme complex, hARD1 and
NATH, were found to interact with ribosomes, probably facil-
itating the acetylation of the a-amino groups of newly synthe-
sized proteins. However, a fraction of hARD1 was also found
to be localized in the nucleus where partial colocalization with
HIF-1a was observed [15].
In Saccharomyces cerevisiae, Nat1p forms a heterodimer
with Ard1p to generate a functional protein N-acetyl transfer-
ase (NatA) [16,17], Ard1p being the catalytic subunit. Proteinsblished by Elsevier B.V. All rights reserved.
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of NatA [18]. NatA was found to directly interact with nascent
polypeptides as well as ribosomes through binding of Nat1p to
the large ribosomal subunit [19]. From an evolutionary point
ARD1 may have evolved from an a-amino acetyltransferase
to an e- and a-amino acetyltransferase, although this is per-
haps not a very likely event. Alternatively, this dual function
could be present also in S. cerevisiae although no such activity
has been described.
Here we provide evidence that contradicts previous reports on
the role of ARD1 in the regulation of the HIF-1a. Our results
indicate that hypoxia does not regulate the level of endogenous
hARD1protein, and that neither overexpression nor silencing of
hARD1 aﬀects the stability of HIF-1a. However, we did ﬁnd a
speciﬁc interaction between HIF-1a and hARD1, suggesting
that a functional link may exist between these two proteins.2. Materials and methods
2.1. Cell culture and transfection
The human cell lines HEK293 cells (embryonal kidney, ATCC:
CRL-1573), HT1080 (ﬁbrosarcoma), RCC4 (renal carcinoma) and
HeLa cells (epithelial cervix adenocarcinoma, ATCC: CCL-2) were
cultured at 37 C, 5% CO2 in DMEM supplemented with 10% FBS
and 3% L-glutamine. MCF-7 cells (breast adenocarcinoma, ATCC:
HTB-22) were cultured as above, but with RPMI1640. Transfections
were performed using Fugene6 (Roche) or Lipofectamine (Invitrogen)
according to the instruction manuals. Hypoxia (1% O2) was conducted
in an oxygen workstation (InVivoO2, Ruskin Technologies) and hy-
poxia mimicking agents were added at concentrations of 200 lM for
CoCl2 and 150 lM for desferroxamine. Plasmid encoding HA-HIF-
1a has been described [20]. Plasmid encoding Xpress-hARD1 was
made by subcloning hARD1 cDNA to pcDNA4 MaxHis (Invitrogen).
siRNAs were from Dharmacon and transfections were performed
using Oligofectamine (Invitrogen) according to the instruction manual.
The following siRNA duplex target sequences were used: si-hARD1
(siA1), CCA GAU GAA AUA CUA CUU C and siLamin A/C
(siL), GGU GGU GAC GAU CUG GGC U.
Tet-inducible ARD1. A tetracycline inducible ARD1 cell line was
established using a modiﬁed BD Tet-on system from BD-Bioscience.
Brieﬂy, HeLa cells (BD cat # 630901) expressing the reverse Tet-repres-
sor (rTetR) were transfected with a pCEP4 expression vector contain-
ing the FLAG-hARD1 cDNA under the control of the tetracycline
responsive element (TRE) and a minimal CMV promoter, as described
[21]. Following selection with G418, the HeLa hARD1 cells were cul-
tured in low Tet-FCS and induced with 1 lg Dox for 48 h before use.
Control cells were created by transfection of rTetR-HeLa with a similar
pCEP4 Tet-responsive plasmid (TRE-Luc) expressing luciferase.
2.2. Western blotting
Western blotting was performed as previously described [22]. In
brief, 12% SDS–PAGE was used for hARD1 and b-tubulin detection,
while 7.5% gels were utilized for detection of HIF-1a. Antibody-
dilutions: anti-NATH 1:500, anti-hARD1 1:500, anti-V5 (Invitrogen)
1:1000, anti-Xpress (Invitrogen) 1:1000, anti-HIF-1a (Pharmigen)
1:500, anti-b-tubulin (Sigma) 1:1000 (loading control), anti-Acetyl-
Lysine (Sigma) 1:500, anti-Acetyl-Lysine (Upstate) 1:1000. Horserad-
ish peroxidase-conjugated anti-mouse and anti-rabbit IgG were from
Amersham Lifescience, UK.2.3. Immunoprecipitation
Immunoprecipitation was performed as described [15]. Approxi-
mately 2 · 106 cells were used per experiment. Cells were lysed 48 h
post-transfection, and then incubated with 30 ll Protein A/G Agarose
beads (Santa Cruz) to preclear the lysate. Then 2 lg antibody was
added for 4 h and thereafter 50 ll Protein A/G Agarose for 16 h. After
several washing steps in PBS, the beads were added sample buﬀer and
analyzed by 7.5% SDS–PAGE and Western blotting using anti-HA
(Sigma) 1:1000.2.4. In vitro interaction and acetylation assays
Full length or deletion constructs of hARD1 cDNA was cloned into
the pETM60 vector (G. Stier, EMBL) using the restriction sites Acc65I
and NcoI. Escherichia coli strain BL21 (DE3) pLysS (Invitrogen) was
used for the protein expression according to the instruction manual.
Puriﬁcation of recombinant hARD1 protein was performed using sev-
eral steps of His-aﬃnity columns and gel ﬁltration with or without
cleavage from the fusion partner NusA using TEV-protease (Invitro-
gen). GST-ODD containing the amino acids 393–580 of HIF-1a was
constructed by cloning the ODD fragment (393–580) into the
pGEX4T-3 vector (Amersham). The GST-ODD K532R mutant was
made by sited-directed mutagenesis using a QuickChange kit from
Stratagene. GST and GST-fusion-proteins were coupled to Sepharose
4B (Amersham). In the interaction assays (Fig. 3B and C), the compo-
nents were allowed to interact for 30 min at 30 C in interaction buﬀer
(2 mM DTT; 10 mM KH2PO4; 10 mM Na2HPO4 Æ 2 H2O; 200 mM
NaCl; 1 tablet Complete EDTA free protease inhibitor (Roche) per
50 ml buﬀer; pH adjusted to 7.4 before use) before the Sepharose beads
were washed three times using the same buﬀer. NusA-ABD (Actin
binding domain) and GST was used as negative controls in the interac-
tion assays. Interaction assays (Fig. 4A) and acetylation assays (Fig. 4B
and C) were performed in acetylation buﬀer (1 mM DTT; 10 mM Na
butyrate; 50 mM Tris–HCl; 800 lM EDTA; 10% glycerol; pH adjusted
to 8.5 before use) for 1 h at 30 C. Input was 3 lg GST-ODD and 1 lg
hARD1. N-a-acetylation assays were performed as previously de-
scribed [15]. Brieﬂy, immunoprecipitation was done as above (Section
2.3) without transfection. Pure hARD1 or pellets of Protein A/G-aga-
rose bound NATH–hARD1 complex was added to 10 ll ACTH
(0.5 mM, human adrenocorticotropic hormone fragment 1–24, Calbio-
chem), 4 ll [3-H]acetyl-coenzyme A (1 lCi, 107 GBq/mmol, Amersham
Biosciences) and 136 ll of 0.2 M K2HPO4 (pH 8.1). The mixture was
incubated at 37 C and samples were collected after 1 h. After centrifu-
gation the supernatant was added to 150 ll SP Sepharose (50% slurry in
0.5 MAcetic acid, Sigma) and incubated on a rotor for 5 min. The mix-
ture was centrifuged and the pellet was washed three times with 0.5 M
acetic acid and ﬁnally with methanol. Radioactivity in the ACTH con-
taining pellet was determined by scintillation counting.3. Results
3.1. Hypoxia does not decrease the level of endogenous hARD1
protein
According to an early work from Jeong et al., hypoxic condi-
tions decreased the level of hARD1 mRNA. Although a recent
study partially conﬁrmed this ﬁnding, downregulation of
hARD1mRNAwasnot consistent in all cell lines [23]. To further
test the role of hypoxia on ARD1, we used a recently developed
antibodyagainst hARD1and evaluated the eﬀect of hypoxia and
hypoxia-mimicks (cobalt and desferroxamine) in several cell
lines. As shown in Fig. 1, the endogenous hARD1 protein did
not decrease signiﬁcantly in diﬀerent cell lines tested: HT1080
and RCC4 cells treated with hypoxia (1% O2) for 18 h
(Fig. 1A) or HeLa cells and HEK293 cells treated with CoCl2
for 6 h (Fig. 1B). Although the stimuli stabilizedHIF-1a protein,
no decrease in the level of hARD1protein was observed.MCF-7
cells treated with CoCl2 at various times between 0 and 18 h
showed a peak of HIF-1a protein level at 6 h after treatment,
while the level of hARD1 was quite stable throughout the treat-
ment (Fig. 1C). Hypoxia treatment of HEK293 cells and HeLa
cells, anddesferroxamine treatment ofHT1080 cells showed sim-
ilar results (data not shown). The results using diﬀerent human
cell lines and diﬀerent hypoxia-mimics strongly suggest that the
level of endogenous hARD1 protein is not regulated by hypoxia.3.2. Stability of HIF-1a is not regulated by hARD1
Jeong et al. had found that hARD1 negatively regulated the
protein stability of HIF-1a and that induced levels of hARD1
Fig. 1. The level of hARD1 protein is stable during hypoxia.
(A) RCC4 and HT1080 cells were exposed to either normoxia (N) or
hypoxia (H) for 18 h and the cell lysates were analyzed by Western
blotting with anti-hARD1. (B) As (A) using HeLa and HEK293 cells
and CoCl2 treatment for 6 h. (C) As (A) adding CoCl2 for the indicated
times to MCF-7 cells.
Fig. 2. hARD1 does not regulate the stability of HIF-1a. (A)
Overexpression of FLAG-hARD1 was induced in a HeLa-Tet induc-
ible cell line under normoxic (N) or hypoxic (H) conditions. Cell
lysates were analyzed by Western blotting with anti-HIF-1a.
(B) hARD1 was knocked down in HeLa cells by siRNAs in the
presence or absence of CoCl2. The level of HIF-1a in the cell lysates
was analyzed by Western blotting.
Fig. 3. hARD1 interacts with HIF-1a. (A) MCF-7 cells were cotrans-
fected by plasmids encoding HA-HIF-1a and Xp-hARD1 (or Xp-lacZ
as a negative control). Immunoprecipitates of the cell lysates using
anti-Xp were analyzed by Western blotting with anti-HA to detect
HA-HIF-1a. (B) GST (negative control) or GST-ODD beads were
incubated with NusA-hARD1 or NusA-ABD (negative control). After
washing steps, the beads were analyzed by SDS–PAGE and Coomassie
staining to determine the level of retained NusA-hARD1/ABD. (C) As
(B) using pure hARD1 and analysis by Western blotting and anti-
hARD1.
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formed overexpression and knock-down of hARD1 and
monitored the levels of endogenous HIF-1a protein. Using
Tet-inducible HeLa cells, we induced overexpression of
FLAG-hARD1 and tested for its eﬀect on HIF-1a under hyp-
oxic and normoxic conditions. Western blot analysis of cell ly-
sates following induction of ARD1 by Tet-treatment revealed
no signiﬁcant changes in HIF-1a levels compared with their
control cell lines (Fig. 2A). Similarly, transient overexpression
of hARD1 in HEK293 cells had no signiﬁcant eﬀect on HIF-
1a levels (not shown).
Suppression of hARD1 by siRNA knock-down also failed to
aﬀect HIF-1a levels either under hypoxic or in normoxic con-
ditions (Fig. 2B). If hARD1 contributes to the destabilization
of HIF-1a in normoxia, then we should have observed a norm-
oxic increase in HIF-1a levels when hARD1 is signiﬁcantly re-
duced by RNAi. The recent study by Bilton et al. found no
regulation of HIF-1a protein as a consequence of up- or down-
regulation of hARD1 [24]. Also Fisher et al. [23] found no sta-
bilization of HIF-1a by RNAi mediated silencing of hARD1.
Taken together, these results indicate that hARD1 is not a reg-
ulator of HIF-1a protein stability.
3.3. hARD1 interacts with HIF-1a in vivo and in vitro
Since there seemed to be no regulation of hARD1 level by
hypoxia and no regulation of HIF-1a by hARD1, we wanted
to investigate whether or not these two proteins interact at
all. The in vivo interaction was analyzed by immunoprecipi-
tation experiments using plasmids encoding HA-tagged
HIF-1a and Xpress-tagged hARD1. MCF-7 cells cotrans-
fected with both plasmids were lysed and subjected to immu-noprecipitation using anti-Xpress. Western blot analysis of
the immunoprecipitates demonstrated that hARD1 co-immu-
noprecipitated with HIF-1a (Fig. 3A). To test the direct
in vitro interaction between hARD1 and the ODD-domain
within HIF-1a, we puriﬁed NusA-hARD1 and GST-ODD.
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with NusA-hARD1 and thereafter washed several times un-
der physiological conditions. The results demonstrated that
a portion of the puriﬁed NusA-hARD1 bound speciﬁcally
to GST-ODD as compared to the negative controls
(Fig. 3B). Binding studies with a deletion mutant containing
amino acids 1–179 of hARD1 also demonstrated speciﬁc
binding to GST-ODD (not shown). Similarly, parallel assays
using pure hARD1 without the NusA fusion partner demon-
strated binding of hARD1 to GST-ODD, but not to GST
(Fig. 3C). Thus, these two proteins directly interact with each
other. The demonstration of a speciﬁc in vivo and in vitroFig. 4. hARD1 does not acetylate HIF-1a. (A) Interaction assay as
Fig. 3C using GST, GST-ODD WT or GST-ODD K532R beads and
acetylation buﬀer with indicated concentrations of Acetyl Coenzyme A
(AcCoA). hARD1 retained on beads after washing was analyzed by
SDS–PAGE and Western blotting with anti-hARD1. (B) Acetylation
assay with GST-ODD and puriﬁed hARD1. Detection of acetylated
GST-ODD by Western blotting and anti-acetyl lysine and by
incorporation of [14-C] acetyl coenzyme A. Coomassie staining veriﬁes
equal loading of GST-ODD. Upper panel: Demonstration of hARD1
activity in ACTH (adrenocorticotropin 1–24) N-a-acetylation assay.
(C) As (B), but with immunoprecipitated NATH–hARD1 complexes
as enzyme. HeLa cellular lysates were immunoprecipitated (IP) with
anti-NATH, anti-hARD1 or rabbit immunoglobulins (Ig) as a
negative control.interaction between hARD1 and HIF-1a is in accordance
with the original ﬁndings of Jeong et al. [14].
3.4. HIF-1a is not acetylated by hARD1
Since ODD (HIF-1a) has been proposed to be a substrate of
hARD1 acetylation [14], one could expect that the addition of
the acetyl donor, acetyl CoA, would allow for the enzymatic
reaction to occur and thus release the substrate from its en-
zyme. The presence or absence of acetyl-CoA in a mixture of
hARD1 and GST-ODD in acetylation assay conditions did
not have any eﬀect on the binding (Fig. 4A). We also mutated
the K532 within ODD reported to be the acetyl acceptor.
Interestingly, the GST-ODD K532R interacted equally strong
with hARD1 as the GST-ODD WT (Fig. 4A). Furthermore,
results of in vitro acetylation assays using puriﬁed GST-
ODD and hARD1 showed no acetylation, as assessed by using
anti-acetyl lysine antibodies (Fig. 4B) or by incorporation of
[14-C]-acetyl coenzyme A. The proper folding of the puriﬁed
hARD1 is supported by the fact that the puriﬁed protein is ac-
tive as an N-a-acetyltransferase and that it is able to speciﬁ-
cally interact with ODD. We also immunoprecipitated
hARD1–NATH complexes from human cell lines and while
these complexes were active in N-a-acetylation assays, they
were not able to acetylate the ODD (Fig. 4C). Concordingly,
the recent study by Bilton et al. also failed in demonstrating
any HIF-1a acetylation by hARD1 in vitro. Thus, ODD does
not seem to be a substrate of hARD1 or hARD1–NATH
mediated acetylation.4. Discussion
Early studies by Jeong et al. suggested that acetylation of
HIF-1a by ARD1 was an important mechanism controlling
HIF-1a stability by enhancing its interaction with VHL and
promoting its ubiquination and degradation. Furthermore, it
was suggested that the levels of ARD1 were negatively regu-
lated by hypoxia conforming to a feedback loop that would al-
low the hypoxic stabilization of HIF-1a protein. Our results
indicate that ARD1 seems not to be regulated by hypoxia at
the mRNA or protein level and hARD1 does not appear to
have an impact on HIF-1a stability. During preparation of this
manuscript similar ﬁndings were reported by Bilton et al. [24].
They found that hARD1 remained stable during hypoxic con-
ditions both at the mRNA and at the protein level. Thus, it
seems clear that a regulation of hARD1, if any, by hypoxic
conditions does not occur through downregulation of hARD1
mRNA or protein. The reported N-e-acetylation of the HIF-
1a-ODD by hARD1 could not be veriﬁed by our experiments
using in vitro acetylation assays with bacterially and mamma-
lian expressed enzymes. Moreover, a K532R mutation at the
putative hARD1 acetylation site did not aﬀect the interaction
between the HIF-1a-ODD and hARD1 (Fig. 4A), neither af-
fected the stability of HIF-1a-ODD in vivo (Kong et al., sub-
mitted). Thus, hARD1 can in our hands only be regarded as an
N-a-acetyltransferase. Our ﬁndings are consistent with the re-
cent observations by Fisher et al. and Bilton et al., who re-
ported that suppression and overexpression of ARD1 did
not aﬀect basal HIF-1a levels or its response to hypoxia. How-
ever, we conﬁrmed that there is a physical interaction between
HIF-1a and hARD1, suggesting that they may be functionally
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strated that hARD1 localized in the nucleus as well as the cyto-
plasm and partially co-localized with HIF-1a in the nucleus
[15]. The demonstrated interaction between HIF-1a and
hARD1 supports that this may take place. Other studies have
shown that little or no hARD1 is present in the nucleus
[14,24,25]. The reason for these discrepancies is unknown,
but the subcellular localization of hARD1 may be regulated.
Future studies are needed to reveal the functional role of the
hARD1-HIF-1a interactions. The NATH–hARD1 N-a-ace-
tyltransferase complex represents so far the only known func-
tion for hARD1. It will be interesting to determine whether the
hARD1-HIF-1a interaction is independent of the NATH–
hARD1 complex. As is described herein for ODD, also NATH
interacts with amino acids 1–179 within hARD1 [15]. It is
therefore possible that hARD1 is not capable of interacting
with both NATH and HIF-1a simultaneously. Other proteins,
like p53 have also been reported to interact with the ODD do-
main within HIF-1a [26]. Further interaction studies are re-
quired to elucidate whether or not the binding of hARD1 to
ODD may aﬀect these interactions.
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